Literature DB >> 34521306

Adrenal insufficiency in HIV/AIDS: a review.

Simon Mifsud1, Zachary Gauci1, Mark Gruppetta1, Charles Mallia Azzopardi2, Stephen Fava1.   

Abstract

INTRODUCTION: Adrenal insufficiency (AI) is one of the most common potentially life-threatening endocrine complications in people living with human immunodeficiency virus (PLHIV) infection and acquired immunodeficiency syndrome (AIDS). AREAS COVERED: In this review, the authors explore the definitions of relative AI, primary AI, secondary AI and peripheral glucocorticoid resistance in PLHIV. It also focuses on the pathophysiology, etiology, diagnosis and management of this endocrinopathy in PLHIV. A literature review was conducted through Medline and Google Scholar search on the subject. EXPERT OPINION: Physicians need to be aware of the endocrinological implications of HIV infection and its treatment, especially CYP3A4 enzyme inhibitors. A high index of clinical suspicion is needed in the detection of AI, especially in PLHIV, as it may present insidiously with nonspecific signs and symptoms and may be potentially life threatening if left untreated. Patients with overt primary and secondary AI require glucocorticoid replacement therapy. Overt primary AI also necessitates mineralocorticoid replacement. On the other hand, the management of relative AI remains controversial. In order to reduce the risk of adrenal crisis during periods of stress, the short-term use of glucocorticoids may be necessary in relative AI.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Adrenal Insufficiency; Glucocorticoid Resistance; Human Immunodeficiency Virus; Relative Adrenal Insufficiency

Mesh:

Substances:

Year:  2021        PMID: 34521306     DOI: 10.1080/17446651.2021.1979393

Source DB:  PubMed          Journal:  Expert Rev Endocrinol Metab        ISSN: 1744-6651


  1 in total

1.  The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System.

Authors:  Emanuel Raschi; Michele Fusaroli; Francesco Massari; Veronica Mollica; Andrea Repaci; Andrea Ardizzoni; Elisabetta Poluzzi; Uberto Pagotto; Guido Di Dalmazi
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.